Navigation Links
SuperGen to Present Data at EORTC-NCI-AACR
Date:10/15/2008

DUBLIN, Calif., Oct. 15 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the company's plans to present five posters at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" on October 23 and 24, 2008.

SuperGen's presentations will review clinical and non-clinical advances in the following compounds: MP-470, SGI-1776 and SGI-1252. All presentations will occur as poster presentations.

Abstract Number/Title Date

Abstract 403: Clinical responses in highly refractory

solid tumor patients with oral MP-470, a multi-targeted

tyrosine kinase inhibitor, in combination with standard

of care chemotherapy regimens: preliminary report from

a multi-institutional phase-1b clinical trial Oct 23

Abstract 332: In vivo activity of SGI-1776, an orally

active Pim kinase inhibitor Oct 23

Abstract 426: Effects of food on the single-dose

pharmacokinetics of oral MP-470 capsules Oct 23

Abstract 480: MP-470, a novel multi-targeted tyrosine

kinase inhibitor targeting RAD 51 is not toxic to human

primary marrow stem cells at clinically relevant

concentrations Oct 24

Abstract 571: Modulation of JAK2 signaling pathways in

vitro and in vivo by SGI-1252, a potent small molecule

JAK2 inhibitor Oct 24

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008
2. SuperGen Reports 2008 Second Quarter Financial Results
3. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
4. SuperGen Reports 2008 First Quarter Financial Results
5. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
6. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
7. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
8. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
9. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
10. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
11. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Array BioPharma Inc. (NASDAQ: ... reached a definitive agreement with Novartis Pharma AG to ... currently in Phase 3 development.  This agreement is conditional on ... PLC (GSK) on April 22, 2014, which are expected to ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Eckert & ... Mass Spectrometry (AMS) services to the pharmaceutical and biotech ... joined the company in the position of Director of ... of broad and valuable experience in drug metabolism and ...
(Date:1/22/2015)... 22, 2015  Transwestern | RBJ today announces the firm brokered ... for Shire a leading biopharmaceutical company, at Two Ledgemont Center ... Robert Richards , president, and Brian Cohen , ... entire five-floor building at 95 Hayden Ave. Photo ...
(Date:1/22/2015)... | RBJ today announces the firm brokered a long-term lease ... leading biopharmaceutical company, at Two Ledgemont Center in ... , president, and Brian Cohen , senior vice president, ... at 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2
... PRINCETON, N.J., Dec. 8 BioWa, Inc., announced today ... its POTELLIGENT(R) Technology for,use in developing and commercializing select ... "GSK is recognized ... drug,discovery," said Dr. Masamichi Koike, BioWa President and CEO. ...
... Dec. 7 Data on Cytopia,s (ASX: CYT) JAK2 inhibitor CYT387 will ... Francisco. The talk will be presented by Dr Thomas Bumm ... CYT387 in an in- vivo model of myeloproliferative disorders. , ... Effects of CYT387, a Potent Novel JAK2 Inhibitor on ...
... Dynamic Alert,Limited (OTC Bulletin Board: DYMC) is pleased ... markets for its pharmaceutical product line-up. The,modalities will ... rapid onset,through oromucosal absorption, topical applications, such as ... Some products will have,specific uses, while others may ...
Cached Biology Technology:BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization 2Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products 2Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products 3
(Date:1/22/2015)... Washington , January 20, 2015 Investorideas.com, ... tech stocks, releases video from the CES 2015 (Consumer Electronics ... Apollo Robbins . Apollo shows how easily ... smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... MUNICH , January 22, 2015 ... its tenth year  The European Patent Office to present ... Two British nominations to be featured: Christofer Toumazou ... week featuring former finalists and winners of the Award   ...
(Date:1/22/2015)... EyeLock, Inc. , a market leader of iris-based identity authentication ... to the new role of Senior Vice President of Mobile ... mobile platforms and wearable solutions for EyeLock,s technologies. Gerber brings ... semiconductor industry to his role at EyeLock, with expertise in ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... Institute have identified a molecular interaction that triggers a ... attacking this target with selective drugs might improve treatment. ... a team led by Qunyan Yu, MD, and Peter ... of a certain mutated oncogene and the newly described ...
... all-important channels that control the flow of information in and ... for the split to come when a cell divides. Now, ... Biological Studies watched as new funnel-like pore structures formed from ... This discovery adds to the picture of how a cell ...
... a gene previously linked to impulsive violence appears ... memory and thinking in humans, researchers at the ... Mental Health (NIMH) have found. Brain scans revealed ... to have relatively smaller emotion-related brain structures, a ...
Cached Biology News:New cellular flaw found in some virulent breast cancers 2New cellular flaw found in some virulent breast cancers 3Researchers solve mystery of how nuclear pores duplicate before cell division 2Aggression-related gene weakens brain's impulse control circuits 2Aggression-related gene weakens brain's impulse control circuits 3
... of Japan, also named Sendai virus) Envelope ... of molecules by means of membrane fusion. ... Protein, Oligo, cDNA, Antibodies, Vector, and Biomolecule ... EX has a high fusing capability in ...
... S. pombe Whole Genome ChIP-on-chip Microarray ... of yeast (S. pombe) DNA binding ... with Agilent DNA microarrays. This set ... data with greater true binding events ...
... designed for easy transformation of the budding ... successful transformation simply by mixing a plasmid ... yeast cells. No complicated steps, such as ... kit is particularly well suited for high-throughput ...
... The STag Purification Kits enable rapid analytical ... fusion proteins produced from appropriate vectors. Sufficient ... to 1 mg target protein under native ... with S-protein Agarose, which specifically retains STag ...
Biology Products: